The observed changes in TCR diversity and the polyfunctionality of CD4+ and CD8+ T cells following combination therapy suggest a potential immunomodulatory mechanism underlying the reversal of AR to ICIs in NSCLC. Here, CD8A is linked to non-small cell lung carcinoma.